How Big Are Gilead's Latest COVID Wins?

The U.S. Food and Drug Administration (FDA) recently expanded the label for Gilead Sciences' (NASDAQ: GILD) COVID-19 therapy Veklury (remdesivir) to be used in treating non-hospitalized adults. In addition, the agency expanded the Emergency Use Authorization (EUA) for the drug to include children below age 12. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli discuss how big these latest COVID-19 wins are for Gilead.

Continue reading

Source Fool.com